MDT

95.62

+0.1%↑

VEEV

286.22

-0.26%↓

A

138.32

+1.29%↑

HQY

93.32

+3.04%↑

PHR.US

22.18

-0.63%↓

MDT

95.62

+0.1%↑

VEEV

286.22

-0.26%↓

A

138.32

+1.29%↑

HQY

93.32

+3.04%↑

PHR.US

22.18

-0.63%↓

MDT

95.62

+0.1%↑

VEEV

286.22

-0.26%↓

A

138.32

+1.29%↑

HQY

93.32

+3.04%↑

PHR.US

22.18

-0.63%↓

MDT

95.62

+0.1%↑

VEEV

286.22

-0.26%↓

A

138.32

+1.29%↑

HQY

93.32

+3.04%↑

PHR.US

22.18

-0.63%↓

MDT

95.62

+0.1%↑

VEEV

286.22

-0.26%↓

A

138.32

+1.29%↑

HQY

93.32

+3.04%↑

PHR.US

22.18

-0.63%↓

Search

Axsome Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

121.01 -0.59

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

118.88

Max

121.88

Pagrindiniai rodikliai

By Trading Economics

Pajamos

11M

-48M

Pardavimai

29M

150M

Pelno marža

-31.973

Darbuotojai

846

EBITDA

20M

-37M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+40.84% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-11-03

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

678M

6B

Ankstesnė atidarymo kaina

121.6

Ankstesnė uždarymo kaina

121.01

Naujienos nuotaikos

By Acuity

42%

58%

156 / 371 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bearish Evidence

Axsome Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-10-13 21:45; UTC

Įsigijimai, susijungimai, perėmimai

Goldman Sachs to Acquire Industry Ventures for Up to $965 Million -- Update

2025-10-13 21:07; UTC

Įsigijimai, susijungimai, perėmimai

Goldman Sachs to Acquire Industry Ventures for Up to $965 Million

2025-10-13 17:03; UTC

Pagrindinės rinkos jėgos

Canaan ADRs Climb on Launch of Gas-to-Computing Pilot in Canada

2025-10-13 23:53; UTC

Rinkos pokalbiai

Gold Rises, Buoyed by Bullish Fundamental Backdrop -- Market Talk

2025-10-13 23:39; UTC

Rinkos pokalbiai

Nikkei May Rise, Tracking Wall Street's Gains -- Market Talk

2025-10-13 22:15; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-10-13 22:15; UTC

Rinkos pokalbiai

Precinct Properties NZ's Equity Raising Looks Opportunistic -- Market Talk

2025-10-13 21:57; UTC

Įsigijimai, susijungimai, perėmimai

Goldman Buys $7B Venture-Capital Firm in Latest Asset-Management Bet -- Barrons.com

2025-10-13 21:36; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-10-13 21:36; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-10-13 21:36; UTC

Rinkos pokalbiai

Fletcher's Near-Term Headwinds Don't Cloud Earnings Opportunity -- Market Talk

2025-10-13 21:30; UTC

Įsigijimai, susijungimai, perėmimai

Goldman Sachs to Acquire Industry Ventures for Up to $965M -- Update

2025-10-13 21:06; UTC

Įsigijimai, susijungimai, perėmimai

Goldman Buys $7B Venture-Capital Firm in Latest Asset-Management Bet -- Barrons.com

2025-10-13 20:52; UTC

Įsigijimai, susijungimai, perėmimai

Goldman Sachs to Acquire Industry Ventures for Up to $965M

2025-10-13 20:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2025-10-13 20:35; UTC

Įsigijimai, susijungimai, perėmimai

Goldman Expects to Close Deal in 1Q

2025-10-13 20:34; UTC

Įsigijimai, susijungimai, perėmimai

Industry Ventures Will Be Part of Goldman's External Manager Platform, External Investing Group

2025-10-13 20:33; UTC

Įsigijimai, susijungimai, perėmimai

Industry Ventures Currently Manages $7B of Assets Under Supervision

2025-10-13 20:32; UTC

Įsigijimai, susijungimai, perėmimai

Goldman Sachs: Deal to Include Up to $300M of Additional Contingent Consideration Based on Future Performance Through 2030

2025-10-13 20:31; UTC

Įsigijimai, susijungimai, perėmimai

Goldman Sachs: Consideration to Include $665M Cash and Equity Payable at Closing

2025-10-13 20:29; UTC

Įsigijimai, susijungimai, perėmimai

Goldman Sachs to Buy VC Firm Industry Ventures

2025-10-13 19:05; UTC

Rinkos pokalbiai

Oil Futures Pick Up on Easing U.S.-China Tension -- Market Talk

2025-10-13 18:59; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

2025-10-13 18:26; UTC

Rinkos pokalbiai

Precious Metals Close at New Record Highs -- Market Talk

2025-10-13 18:10; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-10-13 18:10; UTC

Rinkos pokalbiai

Broadcom's OpenAI Deal Highlights AI Opportunity -- Market Talk

2025-10-13 17:05; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-10-13 17:05; UTC

Rinkos pokalbiai

OpenAI Deal Offers Huge Upside to Broadcom's Earnings -- Market Talk

2025-10-13 16:03; UTC

Įsigijimai, susijungimai, perėmimai

Umicore Completes Sale, Subsequent Lease-in of Permanent Gold Inventories

2025-10-13 15:35; UTC

Rinkos pokalbiai

Precious Metals Push Record Highs Further -- Market Talk

Akcijų palyginimas

Kainos pokytis

Axsome Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

40.84% į viršų

12 mėnesių prognozė

Vidutinis 171.42 USD  40.84%

Aukščiausias 200 USD

Žemiausias 144 USD

Remiantis 16 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Axsome Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

16 ratings

16

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

107.24 / 112.29Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Weak Bearish Evidence

Vidutinės trukmės periodas

Neutral Evidence

Ilgalaikis periodas

Strong Bullish Evidence

Rinkos nuotaikos

By Acuity

156 / 371 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Axsome Therapeutics Inc

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
help-icon Live chat